You are here » Home » Companies » Company Overview » Glaxosmithkline Pharmaceuticals Ltd

Glaxosmithkline Pharmaceuticals Ltd.

BSE: 500660 Sector: Health care
NSE: GLAXO ISIN Code: INE159A01016
BSE 00:00 | 16 Jul 2815.20 -22.65
(-0.80%)
OPEN

2850.00

HIGH

2850.00

LOW

2800.00

NSE 00:00 | 16 Jul 2820.60 -26.45
(-0.93%)
OPEN

2820.35

HIGH

2843.60

LOW

2805.00

OPEN 2850.00
PREVIOUS CLOSE 2837.85
VOLUME 983
52-Week high 2990.00
52-Week low 2040.00
P/E 69.63
Mkt Cap.(Rs cr) 23,845
Buy Price 0.00
Buy Qty 0.00
Sell Price 0.00
Sell Qty 0.00
OPEN 2850.00
CLOSE 2837.85
VOLUME 983
52-Week high 2990.00
52-Week low 2040.00
P/E 69.63
Mkt Cap.(Rs cr) 23,845
Buy Price 0.00
Buy Qty 0.00
Sell Price 0.00
Sell Qty 0.00

Glaxosmithkline Pharmaceuticals Ltd. (GLAXO) - Chairman Speech

Company chairman speech

Dear Shareholders

I am proud to report that in 2017-18 we continued to keep our customers at theforefront of all our endeavours with our initiatives for reach quality and reliablesupply of our medicines. Your Company is firmly committed to serving the unmet andunderserved needs of patients in the country. The Indian healthcare sector continues toundergo rapid changes with the Government driving policies for more access andaffordability of medicines. Technology has enabled us to create fresh avenues to reach ourpatients and doctors in the remotest parts of the country through multiple- locationscientific webinars to create awareness on diseases. We have also made inroads with ourunique initiative of driving our internal doctors in a modified van into remote areas toconduct scientific meetings for rural doctors.

One of the highlights of our year has been that our employees are among the mostengaged in the entire GSK global network. Two global GSK surveys held at six-monthintervals have revealed engagement scores as high as 94% with a majority extremely proudto work for GSK.

Our Corporate Social Responsibility initiatives including our signature initiative toeliminate Lymphatic Filariasis (LF) in India continues with a donation of 40 millionalbendazole tablets during the year to the World Health Organisation. GSK India alongwith GSK UK are in the top quartile in an internal Global Reputation Research surveyconducted among informed public across 13 markets with comparable peers. Corporatereputation is the sum of all the views and beliefs held about a company based on itshistory and confidence in its future.

Our reputation hinges on the trust ofour customers - the faith that they have in thequality and efficacy of our medicines. During the year we were audited for qualitystandards internally by two groups and were rated ‘Acceptable' on A&A and GoodManufacturing Practices (GMP).

Our manufacturing facility in Nashik has been upgraded with significant investment andthe supply that had been impacted during this period has now been restored. This securesreliable supply in our medicines and increases trust with our customers.

We have also taken giant strides in innovation with the launch of our hexavalent DTapvaccine Infanrix Hexa that has been well received by paediatricians. Through anin-licensing deal we also made a foray into infection prevention with Biopatch whichprotects critical care patients at hospitals from hospital-acquired infections CRBSI(catheter-related blood stream infection).

During the year we also saw the implementation of a landmark indirect tax reform - theGoods & Services Tax (GST) creating a single and unified marketwith one-nationone-tax principle that is expected to usher in a new era.

At GSK too we believe that we are at the cusp of a new era. The new direction providedby our Global CEO Emma Walmsley has seen the emergence of three clear priorities -Innovation Performance Trust.

Our goal is to be one of the most innovative best performing and trusted healthcarecompanies in the world. All our group level and business unit goals objectivesstrategies plans emanate from these three priorities resulting in better integratedalignment. It will enable all of us to be more efficient and effective internally andsharply focus our time and energy on delivering externally. These new changes along withour unchanged purpose and values now form a crucial part of our DNA.

India is a key growth market in the Emerging Markets region and we have committed toaccelerating sustained profitable growth to create enduring value for our shareholders. Wewill be driving this performance with fewer but more focussed priorities. This will helpus become more competitive win in the market and serve our patients better. This newapproach is strongly aligned to our Innovation Performance Trust priorities.

With drive and direction we continue with a renewed zeal in our purpose - to enablepeople to do more feel better and live longer. We are confident that the energy willunlock potential and performance delivering consistentvalue to our shareholders.

Accelerating a healthy India with Energy where it matters.

A. Vaidheesh